Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXEL 
Exelixis Inc (EXEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: EXEL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $43.89
1 Year Target Price $43.89
| 7 | Strong Buy |
| 4 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.62% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.61B USD | Price to earnings Ratio 18.96 | 1Y Target Price 43.89 |
Price to earnings Ratio 18.96 | 1Y Target Price 43.89 | ||
Volume (30-day avg) 20 | Beta 0.38 | 52 Weeks Range 31.90 - 49.62 | Updated Date 10/29/2025 |
52 Weeks Range 31.90 - 49.62 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-27 | When Before Market | Estimate 0.6931 | Actual - |
Profitability
Profit Margin 27.01% | Operating Margin (TTM) 37.58% |
Management Effectiveness
Return on Assets (TTM) 17.24% | Return on Equity (TTM) 29% |
Valuation
Trailing PE 18.96 | Forward PE 14.99 | Enterprise Value 10520268243 | Price to Sales(TTM) 4.76 |
Enterprise Value 10520268243 | Price to Sales(TTM) 4.76 | ||
Enterprise Value to Revenue 4.72 | Enterprise Value to EBITDA 13.46 | Shares Outstanding 269202521 | Shares Floating 231837211 |
Shares Outstanding 269202521 | Shares Floating 231837211 | ||
Percent Insiders 2.25 | Percent Institutions 96.53 |
Upturn AI SWOT
Exelixis Inc
Company Overview
History and Background
Exelixis Inc. was founded in 1994 and is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat cancer. Initially involved in genomics research, the company transitioned its focus to cancer therapeutics in the early 2000s. Key milestones include the FDA approval of Cabometyx and Cometriq.
Core Business Areas
- Oncology Therapeutics: Exelixis focuses on developing and commercializing therapies for various types of cancer, including kidney, liver, and thyroid cancers.
- Research and Development: The company invests in research and development to discover new cancer treatments and expand the applications of existing therapies.
Leadership and Structure
The leadership team includes Michael M. Morrissey (President and CEO) and Gisela Schwab, M.D. (President, Product Development & Medical Affairs and Chief Medical Officer). The company operates with a functional organizational structure, with teams dedicated to research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Cabometyx (cabozantinib): Cabometyx is an oral tyrosine kinase inhibitor (TKI) approved for advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC). It holds a significant market share in RCC and HCC treatment. Competitors include drugs from Bristol Myers Squibb (OPDIVO), Merck (KEYTRUDA), and Pfizer (SUTENT).
- Cometriq (cabozantinib): Cometriq, also containing cabozantinib, is approved for progressive, metastatic medullary thyroid cancer (MTC). While it addresses a smaller patient population than Cabometyx, it remains a vital therapy. Competitors are primarily other tyrosine kinase inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by increasing cancer incidence, aging populations, and advancements in cancer treatment. The market is characterized by intense competition, high regulatory hurdles, and the need for continuous innovation.
Positioning
Exelixis is positioned as a leading biopharmaceutical company focused on developing and commercializing differentiated cancer therapies. Its competitive advantages include its focus on TKIs and its established commercial infrastructure. It has a solid track record of successfully developing and marketing cancer drugs.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be hundreds of billions of dollars. Exelixis is positioned to capture a significant share of this market with its existing products and pipeline. The size of the global oncology market was valued at $178.4 billion in 2022 and is projected to reach $376.7 billion by 2032.
Upturn SWOT Analysis
Strengths
- Strong focus on oncology
- Established commercial infrastructure
- Successful track record of drug development
- Robust pipeline of potential new therapies
- Experienced leadership team
Weaknesses
- Reliance on a limited number of products
- High dependence on regulatory approvals
- Competition from larger pharmaceutical companies
- Potential for generic competition
- Pipeline risk
Opportunities
- Expansion into new cancer indications
- Strategic partnerships and collaborations
- Acquisition of complementary technologies
- Growth in emerging markets
- Advancements in personalized medicine
Threats
- Increased competition from new therapies
- Pricing pressures and reimbursement challenges
- Changes in regulatory requirements
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- BAYRY
Competitive Landscape
Exelixis competes with larger pharmaceutical companies that have broader portfolios and greater resources. However, Exelixis' focus on oncology and its successful track record give it a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Exelixis has experienced significant growth in recent years, driven by the success of Cabometyx. Revenue has steadily increased, and the company has expanded its pipeline.
Future Projections: Analysts project continued revenue growth for Exelixis, driven by increasing sales of Cabometyx and potential approvals of new therapies. EPS is also expected to increase.
Recent Initiatives: Recent initiatives include expanding the indications for Cabometyx, advancing its pipeline of novel therapies, and strategic collaborations with other companies.
Summary
Exelixis is a growing biopharmaceutical company with a strong focus on oncology and a successful track record of drug development. The company is well-positioned for future growth, driven by increasing sales of Cabometyx and a robust pipeline. However, it faces competition from larger pharmaceutical companies and is subject to regulatory and market risks. Further expansion into new cancer indications and strategic partnerships are crucial for continued success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Exelixis Inc. SEC Filings, Analyst Reports, Company Presentations
- EvaluatePharma
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Exelixis Inc
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2000-04-07 | CEO, President & Director Dr. Michael M. Morrissey Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1147 | Website https://www.exelixis.com |
Full time employees 1147 | Website https://www.exelixis.com | ||
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.